Serum Concentrations of Orosomucoid: Improved Decision-Making for Tapering Prednisolone Therapy in Patients with Active Inflammatory Bowel Disease?

References

• Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, et al. National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979; 77: 847–69
   PubMed Web of Science ®Google Scholar
• Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment. Gastroenterology 1984; 86: 249–66
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 2: 1041–8
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE, Misiewicz JJ, Connell AM, Baron JH, Jones FA. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet 1965; 1: 188–9
   PubMed Web of Science ®Google Scholar
• Järnerot G, Rolny P, Sandberg-Gertzén H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005–13
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439–44
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841–5
   PubMed Web of Science ®Google Scholar
• Winship DH, Summers RW, Singleton JW, Best WR, Becktel JM, Lenk LF, et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979; 77: 829–42
   PubMed Web of Science ®Google Scholar
• Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067–70
   PubMed Web of Science ®Google Scholar
• Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993; 104: 1293–301
   PubMed Web of Science ®Google Scholar
• André C, Descos L, Landais P, Fermanian J. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut 1981; 22: 571–4
   PubMed Web of Science ®Google Scholar
• Buckell NA, Lennard-Jones JE, Hernandez MA, Kohn J, Riches PG, Wadsworth J. Measurements of serum proteins during attacks of ulcerative colitis as a guide to patient management. Gut 1979; 20: 22–7
   PubMedGoogle Scholar
• Fagan EA, Dyck RF, Maton PN, Hodgson HJF, Chadwick VS, Petrie A, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982; 12: 351–9
   PubMed Web of Science ®Google Scholar
• Brignola C, Iannone P, Belloli C, De Simone G, Bassein L, Gionchetti P, et al. Prediction of relapse in patients with Crohn's disease in remission: a simplified index using laboratory tests, enhanced by clinical characteristics. Eur J Gastroenterol Hepatol 1994; 6: 955–61
   Google Scholar
• Binder V, Both H, Hansen PK, Hendriksen C, Kreiner S, Torp-Pedersen K. Incidence and prevalence of ulcerative colitis and Crohn's disease in the county of Copenhagen 1962to 1978. Gastroenterology 1982; 83: 563–8
   PubMed Web of Science ®Google Scholar
• Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353–6
   PubMed Web of Science ®Google Scholar
• Nielsen H, Petersen PH, Feldt-Rasmussen U, Binder V. Variations in plasma proteins concentrations in individuals with ulcerative colitis: analytical and biological factors. Scand J Clin Lab Invest 1979; 39: 495–502
   PubMed Web of Science ®Google Scholar
• Statland BE, Winkel P, Killingsworth LM. Factors contributing to intra-individual variation of serum constituents. VI. Physiological day-to-day variation in concentrations of 10 specific proteins in sera of healthy subjects. Clin Chem 1976; 22: 1635–8
   PubMed Web of Science ®Google Scholar
• Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964; 1: 89–92
   PubMed Web of Science ®Google Scholar
• Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Blackwell Scientific Publications, Oxford 1994
   Google Scholar
• Statsoft Inc. Statistica for Windows v. 4.3. Statsoft, Tulsa (OK) 1994
   Google Scholar
• Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. J Clin Gastroenterol 1988; 10: 401–5
   PubMed Web of Science ®Google Scholar
• Jensen KB, Jarnum S, Koudahl G, Kristensen M. Serum orosomucoid in ulcerative colitis. Its relation to clinical activity, protein loss, and turnover of albumin and IgG. Scand J Gastroenterol 1976; 11: 177–83
   PubMedGoogle Scholar
• Harris EK, Yasaka T. On the calculation of a ‘reference change’ for comparing two consecutive measurements. Clin Chem 1983; 29: 25–30
   PubMed Web of Science ®Google Scholar
• Boyd JC, Harris EK. Utility of reference change values for the monitoring of inpatient laboratory data. Optimal use of the clinical laboratory. 5th International Meeting: Clinical Laboratory Organization and Management, O Zinder. Karger, Haifa, BaselIsrael 1985; 111–22; 1986
   Google Scholar
• Harris EK, Brown SS. Temporal changes in the concentrations of serum constituents in healthy men. Distribution of within-person variances and their relevance to the interpretation of differences between successive measurements. Ann Clin Biochem 1979; 16: 169–76
   PubMed Web of Science ®Google Scholar
• Kjeldsen J. Treatment of ulcerative colitis with high doses of oral prednisolone. The rate of remission, the need for surgery, and the effect of prolonging the treatment. Scand J Gastroenterol 1993; 28: 821–6
   PubMed Web of Science ®Google Scholar
• Meyers S, Lerer PK, Feuer EJ, Johnson JW, Janowitz HD. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Result of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987; 9: 50–4
   PubMed Web of Science ®Google Scholar
• Truelove SC, Willoughby CP, Lee EG, Kettlewell MGW. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2: 1086–8
   PubMed Web of Science ®Google Scholar
• Dickinson RJ, Ashton MG, Axon ATR, Smith RC, Yeung CK, Hill GL. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980; 79: 1199–204
   PubMed Web of Science ®Google Scholar
• McIntyre PB, Powell-Tuck J, Wood SR, Lennard-Jones JE, Lerebours E, Hecketsweiler P, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986; 27: 481–5
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360–2
   PubMed Web of Science ®Google Scholar
• Modigliani R, Mary J-Y, Simon J-F, Cortot A, Soule J-C, Gendre J-P, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterology 1990; 98: 811–8
   PubMed Web of Science ®Google Scholar
• Landi B, N'Guyen Anh T, Cortot A, Soule JC, Rene E, Gendre JP, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. Gastroenterology 1992; 102: 1647–53
   PubMed Web of Science ®Google Scholar
• Brignola C, De Simone G, Iannone P, Belloli C, Evangelisti A, Campieri M, et al. Influence of steroid treatment's duration in patients with active Crohn's disease. Agents Actions 1992; C90–2
   PubMedGoogle Scholar
• Wright JP, Alp MN, Young GO, Tigler-Wybrandi N. Predictors of acute relapse of Crohn's disease. A laboratory and clinical study. Dig Dis Sci 1987; 32: 164–70
   PubMed Web of Science ®Google Scholar
• Fantuzzi G, Ghezzi P. Glucocorticoids as cytokine inhibitors: role in the neuroendocrine control and therapy of inflammatory diseases. Mediators Inflam 1993; 2: 263–70
   PubMedGoogle Scholar
• Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621–36
   PubMed Web of Science ®Google Scholar
• Kushner I. Regulation of the acute phase response by cytokines. Perspec Biol Med 1993; 36: 611–22
   PubMed Web of Science ®Google Scholar
• Kirkwood BR. Essentials of medical statistics. Black-well Scientific Publications, Oxford 1988
   Google Scholar
• Saverymuttu SH, Hodgson HJF, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986; 27: 809–13
   PubMed Web of Science ®Google Scholar
• Mazlam MZ, Hodgson HJF. Interrelations between interleukin-6, interleukin-β, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut 1994; 35: 77–83
   PubMed Web of Science ®Google Scholar
• Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978; 13: 833–7
   PubMed Web of Science ®Google Scholar
• Löfberg R, Danielsson Å, Suhr O, Nilsson A, Schioler R, Nyberg A, et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996; 110: 1713–8
   PubMed Web of Science ®Google Scholar